Join the Oncology Voice Network. Join for Free
The ART of breaking out of your comfort zone
Introversion in MSL overcoming fear in medical science building a personal brand in healthcare networking for introverts success strategies for MSLs

The ART of breaking out of your comfort zone


Share This Article


Summary

In this episode, Cathy Andorfer joins Tom Caravela to discuss the unique challenges and advantages that introverts face within the medical science liaison (MSL) role. They explore the science behind introversion and extroversion, emphasizing the importance of overcoming fear and developing resilience. Cathy shares personal experiences and insights from her upcoming book, offering advice on goal setting, networking, and the significance of building a personal brand while staying authentic. The conversation wraps up with year-end reflections and the importance of being present in one's current role. The episode concludes with closing remarks, future episode teasers, and a reminder to subscribe.

Cathy Andorfer, US Field Medical Dermatology Lead at Bristol Myers Squibb discusses the art of breaking out of your comfort zone

Cathy shares…

👉 The difference between an introvert and an extrovert

👉 How introverts can find success in Medical Affairs

👉 Advice for extroverts on improved engagement

👉 Tips on how to do things that may terrify you

👉 Why “reflection” is so important and how to use it

Click for Source
Introversion in MSL, overcoming fear in medical science, building a personal brand in healthcare, networking for introverts, success strategies for MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN